Dr Reddys Laboratories Ltd

{"amount":8}

{"actualRevenue":85721000000,"estimateRevenue":89177000000,"revenueSurprise":-3456000000,"revenueSurprisePercent":-3.875438734202765,"actualEPS":17.02,"estimateEPS":18.249228,"surprise":-1.229228000000003,"surprisePercent":-6.735780823166889}

{"actualRevenue":88283000000,"estimateRevenue":89633000000,"revenueSurprise":-1350000000,"revenueSurprisePercent":-1.506141711200116,"actualEPS":16.17,"estimateEPS":17.67558,"surprise":-1.505579999999998,"surprisePercent":-8.517853445261759}

{"actualRevenue":75464000000,"estimateRevenue":84105000000,"revenueSurprise":-8641000000,"revenueSurprisePercent":-10.27406218417454,"actualEPS":2.65,"estimateEPS":11.402784,"surprise":-8.752784,"surprisePercent":-76.7600614025487}

{"actualRevenue":87534000000,"estimateRevenue":85484000000,"revenueSurprise":2050000000,"revenueSurprisePercent":2.398109587759113,"actualEPS":14.52,"estimateEPS":13.8691644,"surprise":0.6508355999999988,"surprisePercent":4.69268069242873}

{"description":"Dr. Reddy's launched Bosutinib Tablets 400 mg in the US, the first generic Bosulif version, with 180-day first-to-file exclusivity and exclusive US marketing rights via MSN Laboratories.","url":"https://www.cnbctv18.com/market/dr-reddy-laboratories-share-price-launches-first-generic-version-of-bosulif-in-us-market-ws-l-19925297.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Dr. Reddy’s reported a 86% drop in Q4 profit to ₹221 crore on lower sales and multiple one-offs, underscoring margin pressure in the latest quarterly results.","url":"https://www.thehindu.com/business/Industry/dr-reddys-q4-dips-86-on-lower-sales-multiple-one-offs-to-221-crore/article70973283.ece","sentiment":"Negative","domain":"The Hindu"}

{"description":"Dr Reddy's shares are in focus after Q4 results showed profit plunging 86% year-on-year; the company also recommended a final dividend of Rs 8, while brokerages stayed divided on the stock.","url":"https://www.msn.com/en-in/money/markets/dr-reddy-s-share-price-in-focus-after-q4-results-profit-plunges-86-yoy-brokerages-remain-divided-on-pharma-stock-do-you-hold/ar-AA2332Go?ocid=BingNewsVerp","sentiment":"Negative","domain":"ET Now on MSN"}

{"description":"Dr Reddy's shares swung on 13 May after Q4FY26 profit fell 86% YoY to ₹220 crore, with revenue down 11.6% and EBITDA down 60%; broker views were mixed and targets were cut.","url":"https://www.livemint.com/market/stock-market-news/dr-reddy-share-rise-3-despite-a-86-yoy-decline-in-q4-profit-should-you-buy-11778648272293.html","sentiment":"Negative","domain":"Mint"}

{"description":"Dr Reddy’s Q4 FY26 net profit fell 86.2% to ₹220 crore as Revlimid competition, margin erosion and one-offs hit earnings; revenue dropped 12% and EBITDA margin shrank to 13%.","url":"https://www.cnbctv18.com/market/earnings/dr-reddys-q4-profit-crashes-as-cancer-drug-revlimid-competition-margin-erosion-hurts-generic-pharma-co-ws-l-19904059.htm","sentiment":"Negative","domain":"CNBCTV18"}